Pallawi Torka, MD, Oncology, Buffalo, NY, Roswell Park Comprehensive Cancer Center

PallawiTorkaMD

Oncology Buffalo, NY

Hematologic Oncology

Assistant Professor of Oncology.

Dr. Torka is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Torka's full profile

Already have an account?

Summary

  • Dr. Pallawi Torka is an oncologist in Buffalo, NY and is affiliated with Roswell Park Comprehensive Cancer Center. She received her medical degree from Jawaharlal Institute of Postgraduate Medical Education and Research and has been in practice 12 years. She also speaks multiple languages, including Hindi and Tamil. She specializes in hematologic oncology and is experienced in b-cell lymphomas, t-cell lymphomas, hodgkin's lymphoma, multiple myeloma, and t-cell and nk-cell lymphproliferative disorders.
  • A Bright Future for Hodgkin Lymphoma | The Bloodline with LLS

    Join us on this episode as Alicia and Lizette from The Leukemia & Lymphoma Society (LLS) speak with Dr. Pallawi Torka, Assistant Professor of Oncology and Co-Pr

Education & Training

  • Jawaharlal Institute of Postgraduate Medical Education and Research
    Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 2006, MBBS
  • SUNY Upstate Medical University
    SUNY Upstate Medical UniversityResidency, Internal Medicine
  • Roswell Park Cancer InstituteFellowship, Medical Oncology

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2016 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Abstracts/Posters

  • Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
    Pallawi Torka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL
    Pallawi Torka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Pallawi Torka, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Cancer Centers Share the Steps They’re Taking to Keep Patients with Compromised Immune Systems Safe from the Coronavirus
    Cancer Centers Share the Steps They’re Taking to Keep Patients with Compromised Immune Systems Safe from the CoronavirusFebruary 13, 2020 01:18
  • Immune Profiling in Non-Hodgkin Lymphoma Patients Receiving AHCT
    Immune Profiling in Non-Hodgkin Lymphoma Patients Receiving AHCTNovember 12, 2019 21:13

Committees

  • Member, NCCN T-cell Lymphoma Committee
  • Member, NCCN Primary Cutaneous B-cell Lymphoma Committee

Professional Memberships

Other Languages

  • Hindi, Tamil

Hospital Affiliations